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Iron-regulatory proteins: molecular
biology and pathophysiological
implications
Gaetano Cairo* and Stefania Recalcati
Iron is required for key cellular functions, and there is a strong link between iron
metabolism and important metabolic processes, such as cell growth, apoptosis
and inﬂammation. Diseases that are directly or indirectly related to iron
metabolism represent major health problems. Iron-regulatory proteins (IRPs)
1 and 2 are key controllers of vertebrate iron metabolism and post-
transcriptionally regulate expression of the major iron homeostasis genes.
Here we discuss how dysregulation of the IRP system can result from both
iron-related and unrelated effectors and explain how this can have important
pathological consequences in several human disorders.
Iron is essential for life but can also catalyse the
formation of reactive oxygen species (ROS) that
can lead to cell damage. Therefore, iron must be
safely bound by specialised proteins to keep
‘free’ iron levels as low as possible. To achieve
this, the control of genes encoding proteins
involved in iron uptake, utilisation, storage and
export must be tightly coordinated. This
challenging task is mainly performed by the
iron-regulatory proteins (IRPs), which control
intracellular iron metabolism, and hepcidin,
which regulates body iron homeostasis (Ref. 1).
Detailed reviews of IRP structure and regulation
have recently been published elsewhere (Refs 2,
3, 4, 5, 6, 7, 8); here, we focus on the role of IRPs
in maintaining intracellular iron homeostasis
and the pathophysiological implications caused
by alterations in this function.
The cloning of genes encoding the H and L
subunits of the iron-storage protein ferritin led
to the identiﬁcation of iron-responsive elements
(IREs) in the 50 untranslated regions (UTRs).
IREs were found to control gene expression in
response to changes in the iron level (Refs 9, 10).
Cytosolic proteins that speciﬁcally recognise and
bind IREs (IRP1 and IRP2) were later identiﬁed
(Refs 11, 12), and subsequently the identiﬁcation
of ﬁve IRE motifs in the 30 UTR of the mRNA
for transferrin receptor 1 (TfR1) (approved gene
symbol TFRC) (Ref. 13), which controls cellular
iron uptake, indicated that IRPs might be the
common regulators of genes involved in iron
homeostasis. Indeed, several genes of iron
metabolism are now known to be controlled
post-transcriptionally through the IRE–IRP
regulatory network (see below).
Soon after its identiﬁcation, it was recognised
that IRP1 (approved gene symbol ACO1)i sa
‘moonlighting’ protein that can perform two
entirely different functions: when present as an
apoform, it is able to bind IRE and control gene
expression; however, IRP1 can also assemble
Institute of General Pathology, University of Milan School of Medicine, Milan, Italy.
*Corresponding author: Gaetano Cairo, Institute of General Pathology, University of Milan, Via
Mangiagalli 31, 20133 Milan, Italy. Tel: +39 0250315350; Fax: +39 0250315338; E-mail: gaetano.
cairo@unimi.it
expert reviews
http://www.expertreviews.org/ in molecular medicine
1
Accession information: DOI: 10.1017/S1462399407000531; Vol. 9; Issue 33; December 2007
&2007 Cambridge University Press
I
r
o
n
-
r
e
g
u
l
a
t
o
r
y
p
r
o
t
e
i
n
s
:
m
o
l
e
c
u
l
a
r
b
i
o
l
o
g
y
a
n
d
p
a
t
h
o
p
h
y
s
i
o
l
o
g
i
c
a
l
i
m
p
l
i
c
a
t
i
o
n
sa [4Fe–4S] cluster and become the cytosolic
counterpart of mitochondrial aconitase. The
switch between the two forms is mainly
regulated by the availability of iron in the
so-called labile iron pool (LIP), a pool of
metabolically available iron whose nature is
difﬁcult to characterise, but whose importance is
widely recognised (Ref. 14). Therefore, this
characteristic makes IRP1 both a sensor of iron
levels within the cell and a regulator of cellular
iron homeostasis (reviewed by Refs 2, 3, 4, 5,
6, 7, 8).
Two bands were evident in the ﬁrst published
example of an IRP–IRE bandshift assay (Ref. 11),
and cloning of the human cDNA led to the
discovery of the second IRP, which was very
similar to IRP1 (Ref. 15). However, the role of
IRP2 (approved gene symbol IREB2)w a s
somewhat neglected until it was demonstrated
that it regulates cellular iron homeostasis
(Ref. 16) and is itself regulated by speciﬁc
pathophysiological stimuli (Ref. 4).
Cellular iron metabolism
The ﬁne adjustment of intracellular iron levels is
mainly achieved by means of a divergent but
coordinated regulation of the iron-storage
protein ferritin and the iron-uptake protein
TfR1. Although transcriptional regulation of the
ferritin heavy and light subunits (H-ferritin and
L-ferritin, respectively) (see Refs 4, 17 for
reviews) and of the TFRC gene (Refs 18, 19) in
response to iron has been described, these two
proteins are mainly controlled at the post-
transcriptional level through the IRE–IRP
system. Over the past decade it has been shown
that other genes involved in iron uptake, release
and utilisation are also controlled by the IRE–
IRP regulatory network (see below).
IRP1 and IRP2 are cytoplasmic proteins
belonging to the aconitase superfamily and
regulate intracellular iron metabolism by
binding with high afﬁnity and speciﬁcity to
conserved IREs in the UTRs of mRNA (Fig. 1)
(Refs 2, 3, 4, 5, 6, 7, 8). In spite of the
predominantly cytosolic localisation of IRPs,
microscopic and biochemical approaches
identiﬁed a fraction (10%) of IRP1 (but not
IRP2) that is associated in a phosphorylation-
dependent manner with Golgi and endoplasmic
reticulum membranes, although the role of
membrane-bound IRP1 is still undeﬁned
(Ref. 20). Under conditions of iron deﬁciency,
IRPs actively bind to IREs and stabilise TfR1
mRNA while also decreasing translation of
ferritin mRNA, eventually increasing the
uptake and availability of iron within the cell.
Conversely, high iron levels decrease IRE-
binding activity, leading to efﬁcient translation
of ferritin mRNA and decreased stability of
TfR1 mRNA, favouring iron sequestration over
uptake (Fig. 1).
IRP1 is the cytoplasmic counterpart of
mitochondrial aconitase, the enzyme that
converts citrate to isocitrate through a cis-
aconitate intermediate in the tricarboxylic acid
cycle by means of a catalytic [4Fe-4S] cluster
(Ref. 21). In iron-replete cells the cluster is
assembled and IRP1 displays aconitase activity;
in iron-depleted cells, no cluster is formed and
apo-IRP1 functions as an RNA-binding protein
(Fig. 2). IRE binding is also controlled by the
redox state of cysteine residues involved in
cluster coordination (Refs 22, 23). Therefore, it
has been proposed that a reversible switch
between a cluster-containing holoprotein and a
cluster-deﬁcient apoprotein allows aconitase/
IRP1 to constantly sense iron levels and to adapt
them to cell requirements without changes in
protein levels. However, apo-IRP1 is also subject
to iron-dependent degradation (Refs 24, 25)
(Fig. 2), and crystallographic studies did not
predict the direct insertion of the cluster in the
apo-IRP1 bound to mRNA (Ref. 26). Therefore,
the idea that a single molecule can reversibly
assume both forms perhaps needs to be revised;
IRP1 exists predominantly in an aconitase form
(Refs 27, 28, 29) and de novo formation of either
IRP1 or aconitase can be stimulated, depending
on iron scarcity or availability, respectively.
Inresponsetoincreasedironlevels,apo-IRP1is
more likely to be degraded than to assemble a
[4Fe-4S] cluster, whereas the loss of all four iron
atoms that convert cytoplasmic aconitase to the
RNA-binding form can probably occur only in
response to oxidative or nitrative stress (see
below). In addition, it has been shown that
protein-kinase-C-dependent phosphorylation
controls both the RNA-binding and aconitase
activities of IRP1 and inﬂuences the
mechanisms of IRP1 regulation in response to
iron (reviewed by Ref. 7) (Fig. 2).
IRP2 is highly homologous to IRP1 but lacks
aconitase activity, probably because of its
inability to assemble a [4Fe–4S] cluster. The
protein accumulates in iron-deﬁcient cells and
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sisrapidlytargetedforproteasomaldegradationin
iron-replete cells (Ref. 30) (Fig. 2). IRP2 binds
consensus IRE sequences with an afﬁnity and
speciﬁcity similar to that of IRP1 (Refs 2, 5), but
it has been shown to recognise an exclusive
subset of IRE-like motifs (Refs 31, 32).
Furthermore, growing evidence suggests that
IRP2 may play a speciﬁc role independently of
aconitase/IRP1. IRP2 is speciﬁcally modulated
in response to stimuli and agents other than
iron, such as hypoxia (Refs 33, 34) and
oxidative stress characterised by enhanced
production of ROS (Refs 35, 36, 37) or reactive
nitrogen intermediates (RNIs) (Refs 38, 39)
(Fig. 2). Moreover, IRP2 expression varies
greatly between tissues (Refs 2, 40). IRP2 is
more sensitive than IRP1 to variations of iron in
the diet (Ref. 28), is expressed at high levels in
most cell lines (Ref. 41) and, when abundantly
(Ref. 42) or uniquely (Ref. 16) expressed, can act
as the major or only modulator of intracellular
iron metabolism, as also indicated by studies in
cells in which either IRP1, IRP2 or both were
knocked down (Ref. 43).
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Figure 1. Regulation of cellular iron homeostasis by the iron-regulatory proteins. Under conditions of iron
deﬁciency, iron-regulatory proteins IRP1 and IRP2 bind to the iron-responsive elements (IREs) located in either
the 50 or 30 untranslated regions (UTRs) of the indicated mRNAs, thus repressing mRNA translation (a) or
preventing mRNA degradation (b), respectively. Increased iron levels result in the loss of IRP afﬁnity for IRE,
causing increased translation of 50 IRE-containing mRNAs (a, right) and degradation of 30 IRE-containing
mRNAs (b, right). The functional role of IRE in some mRNAs remains unclear. mRNAs containing non-
canonical IREs are indicated with a question mark. Abbreviations: APP, amyloid precursor protein; CDC14A,
cell division cycle 14 homologue A; DMT1, divalent metal transporter 1; eALAS, erythroid aminolevulinate
synthase; HIF-2a, hypoxia-inducible factor 2a; mAconitase, mitochondrial aconitase; MRCKa, myotonic
dystrophy-related CDC42-binding kinase a; SDH Drosophila, Drosophila succinate dehydrogenase.
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sGene-targeting experiments have provided
additional information about the respective role
of the two IRPs. Early embryonic lethality in
mice doubly deﬁcient for both IRPs (Ref. 44)
shows that the IRP–IRE regulatory system is
essential. However, mice lacking either IRP1 or
IRP2 are viable, thus indicating that the two
IRPs can compensate for each other. Irp2
2/2
mice display mild microcytosis and compromised
haematopoiesis with abnormal body iron
distribution (Refs 45, 46, 47, 48) and either late-
onset neurodegeneration (Refs 49, 50) or a mild
neurological phenotype (Ref. 51) in different
mouse lines; however, mice lacking IRP1 present
with no detectable phenotypic abnormality
( R e f .5 2 ) .T h e r e f o r e ,I R P 2s e e m st od o m i n a t et h e
regulation of iron homeostasis in animal models
under normal conditions. Extensive investigation
of the comparative expression of the two IRPs in
human tissues and blood cells suggested that
IRP2 is also the key regulator of intracellular iron
homeostasis in humans (Ref. 29). The above
indications of the minor role of IRP1 have been
challenged by recent results obtained in anaemic
zebraﬁsh, which showed that IRP1 regulates
expression of IRE-containing mRNA for erythroid
aminolevulinate synthase (eALAS) and hence has
a role in haem synthesis (Ref. 53).
IRE-containing mRNAs
InadditiontomodulatingferritinandTfR1levels,
IRPs can regulate the mRNAs for other proteins.
IRE structures have been detected in several
mRNAs encoding proteins related to iron
utilisation (eALAS; mitochondrial aconitase,
approved gene symbol ACO2; Drosophila
succinate dehydrogenase, gene symbol SDHB),
uptake [divalent metal transporter 1 (DMT1),
ofﬁcial symbol SLC11A2] and release
(ferroportin, gene symbol SLC40A1) (Refs 2, 3,
4, 5, 6, 7, 8). All these mRNAs except that
encoding one splicing form of DMT1 – which
contains an IRE-like structure in its 3’ UTR and
is upregulated by iron deﬁciency (Ref. 54) –
have one IRE in their 50 UTR and are therefore
regulated at the translational level (Fig. 1),
although the extent of regulation varies
between different transcripts (Ref. 55).
However, recent ﬁndings indicate that the
inﬂuence of IRPs extends over a number of
regulatory pathways not directly related to iron
homeostasis. In particular, integrated strategies
utilising a variety of approaches led to the
P
[4Fe–4S]
cluster
IRE–IRP1
binding
IRE–IRP2
binding
IRE
ROS
Fe2+, RNIs, ROS
H 2O 2, RNIs,
DOXol
Hypoxia, Fe 2+ 
Hypoxia
cAconitase
Proteosomal
degradation
IRE
IRP1
IRP2
IRP1
degradation
Phosphorylation
ROS
a
b
Effect of iron and other signals on 
the IRE–IRP regulatory system
Expert Reviews in Molecular Medicine 2007 
© 2007 Cambridge University Press
Figure 2. Effect of iron and other signals on the
IRE–IRP regulatory system. (a) Regulation of iron-
regulatory protein IRP1. The conversion of IRP1 into
different isoforms is controlled by several effectors.
Hypoxia and high iron levels (Fe
2þ)f a v o u rt h e
formation of the [4Fe–4S] cluster-bearing cytosolic
aconitase (cAconitase). RNIs, DOXol and
administration of extracellular H2O2 favour cluster
disassembly and the acquisition of RNA-binding
activity. ROS cause loss of both aconitase and IRE-
binding activities by inducing the formation of a
degradation-prone intermediate. Phosphorylation
favours [4Fe–4S]-cluster-independent regulation of
IRP1 in response to iron. (b) Regulation of IRP2.
Increased iron levels and exposure to conditions
favouring the formation of ROS and RNIs promote
the degradation of IRP2 by the proteasome, whereas
hypoxia leads to IRP2 stabilisation. Abbreviations:
DOXol, doxorubicinol; IRE, iron-responsive element;
IRP , iron-regulatory protein; RNI, reactive nitrogen
intermediate; ROS, reactive oxygen species.
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sidentiﬁcation of novel IRE-containing genes
(Fig. 1). Myotonic-dystrophy-related CDC42-
binding kinase a (MRCKa) is a kinase that acts
downstream of small GTPases known to be
involved in cytoskeletal regulation and has an
IRE in its 3’ UTR. This IRE may mediate a
similar response to iron as TfR1, albeit of lower
intensity (Ref. 56).
A functional IRE has been found in a
differentially spliced mRNA isoform encoding
CDC14A (cell division cycle 14 homologue A), a
phosphatase involved in the regulation of critical
cell cycle proteins that has been suggested to be
a tumour suppressor (Ref. 57). Although it is not
known how IRPs regulate CDC14A expression,
this ﬁnding reveals interesting links between
iron metabolism and cell cycle regulation,
particularly in light of recent ﬁndings connecting
iron-depletion-mediated growth suppression
at the G1–S transition with a mechanism
regulating cyclin D1 expression (Ref. 58).
A functional IRE has also been found in the
mRNA for the hypoxia-inducible factor (HIF) 2a
(gene symbol EPAS1), a transcription factor that
is activated by lack of oxygen or iron (Ref. 59).
This result, which suggests a negative feedback
control of the HIF-mediated response under
conditions of limited iron availability, may shed
further light on the link between iron and
oxygen homeostasis (see below).
When considering that brain iron homeostasis
is known to be disrupted in several
neurodegenerative disorders (Ref. 60), the
reported presence of an IRE-like motif in the
50 UTR in mRNA of a-synuclein (Ref. 61), a
presynaptic protein that accumulates in several
brain disorders including Parkinson disease, and
APP (amyloid precursor protein) (Ref. 62), is
particularly intriguing. However, it should be
kept in mind that the sequences are not canonical
IREs, and IRE-like motifs found in other mRNAs
have turned out to be nonfunctional (Refs 63, 64).
Often, the iron regulation of these IRE-containing
mRNAs is much lower than those of ferritin and
TfR1 (Refs 4, 6).
Oxidative stress, inﬂammation,
xenobiotics and hypoxia affect IRPs
The regulation of IRPs under conditions of
oxidative stress – that is, in the presence of an
excess of ROS – has been the subject of
intensive research and some debate. Early
observations showed a rapid upregulation of
IRP1 in cells exposed to exogenous H2O2
(reviewed by Refs 2, 3, 4, 38), a transient effect
that is permissive to later induction of ferritin
(Ref. 65) and that seems to be due to the
pleiotropic effects of H2O2 on iron metabolism,
rather than to a direct effect of oxidative stress
on IRP1 activity (Ref. 66). However, studies in
several types of cell line, as well as in vivo,
have shown that a number of conditions or
agents known to increase cellular levels of H2O2
and O2
 2 were able to induce reversible
inactivation of IRP1 (Refs 35, 67, 68, 69, 70).
This body of evidence has led to the conclusion
that IRP1 downregulation, aimed at decreasing
TfR1 levels while also increasing ferritin levels
and hence diminishing the LIP, may be a
common response to prevent enhanced
formation of ROS (Fig. 2). In line with this,
increased ferritin synthesis has been
documented in a variety of cell types exposed
to oxidative stimuli (Refs 4, 17, 38), whereas
reduced oxidative damage has been observed in
cells overexpressing H-ferritin (Refs 71, 72, 73).
IRP2 is an additional target of ROS produced
under conditions of oxidative stress. Available
data suggest that IRP2 is highly sensitive to
ROS-induced downregulation; this may be
triggered by oxidative modiﬁcations of sensitive
residues and could lead to ubiquitin-dependent
proteasomal digestion (Ref. 30) (Fig. 2). Thus,
IRP2 promptly undergoes inactivation in rat
liver exposed to glutathione depletion or
ischaemia–reperfusion (Refs 35, 68), as well as
in cells exposed to menadione (Ref. 70).
IRP2 is not downregulated in cells exposed
to exogenous H2O2 (Refs 2, 3, 4, 38),
conﬁrming that extracellular H2O2 acts through
mechanisms independently of oxidative stress.
On balance, there is solid evidence to conclude
that both IRP1 and IRP2 serve as controllable
targets of intracellularly produced ROS. This
provides the cell with a regulatory loop to
reduce the LIP and prevent further oxidative
damage.
IRPs may also be direct or indirect targets of
RNIs (Fig. 2); in fact, iron–sulphur clusters
have long been recognised as molecular targets
of nitric oxide (  NO). Therefore, several
studies have addressed whether endogenously
generated or exogenous   NO may inﬂuence
iron metabolism by attacking the [4Fe–4S]
cluster of cytoplasmic aconitase/IRP1. Several
reports have shown that   NO does increase
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sIRP1 activity, although the precise mechanism(s)
of such activation remain unclear: some
investigators have suggested that   NO attacks
the [4Fe–4S] cluster of cytoplasmic aconitase,
inducing its disassembly to form IRP1
(reviewed by Refs 2, 3, 4, 38, 74), whereas
others suggest that   NO acts by inducing
cellular iron release and decrease of the LIP
(Refs 2, 3, 4, 38, 74), although these two events
may not be mutually exclusive. Other RNIs,
such as the nitrosonium ion (NO
þ), which
nitrosylates thiol groups of proteins, may have
other effects. In fact, it has been reported
that treatment of human erythroleukaemia
K562 cells with an NO
þ donor decreased
the RNA-binding activity of both IRP1 and
IRP2 (reviewed by Ref. 75). Whereas IRP1 is
susceptible to activation under deﬁned
conditions, IRP2 is almost invariably
inactivated by RNIs, which causes redox
modiﬁcations of the residues that are exposed
by the [4Fe–4S] cluster-free IRP2 followed by
proteasome-mediated protein degradation
(Refs 2, 3, 4, 38, 74, 76) (Fig. 2).
From a pathophysiological viewpoint, RNI-
induced inactivation of IRP2 may be of greater
relevance than a concomitant activation of
IRP1-binding activity because IRP2 is highly
expressed in macrophages, which are key
cells of inﬂammatory processes. IRP2
downregulation may therefore account for the
enhanced ferritin synthesis and reduced TfR1
mRNA content observed in cytokine-stimulated
macrophages producing   NO or ONOO
2
(Refs 42, 76). The described downregulation of
IRP1 protein levels may contribute to the
maintenance of such responses (Ref. 77). Total
IRP activity (IRP1 plus IRP2) of human
monocytes and macrophages tends to rise
shortly after treatment with cytokines or   NO
donors, but then decreases markedly
accompanied by an enhanced ferritin content
(Ref. 78), similarly to the downregulation of
IRP2 in mouse macrophage lines (Ref. 42). The
effects of RNIs on IRPs may therefore explain
the iron-sequestration pattern that characterises
macrophages under inﬂammatory conditions.
The cardiotoxicity induced by doxorubicin
(DOX), an antitumour anthracycline that
also causes a severe form of chronic
cardiomyopathy, provides an excellent model to
investigate whether IRPs may also be the target
of xenobiotics (Refs 79, 80). Three independent
studies have shown that the combined action
of an alcohol metabolite of DOX (DOXol),
which delocalises iron from the [4Fe–4S]
cluster of cytoplasmic aconitase, and O2
 2 and
H2O2 derived from redox activation of
DOX, eventually converts IRP1 into a ‘null’
protein, which lacks both aconitase and
RNA-binding activities (Refs 81, 82, 83) (Fig. 2).
According to another study (Ref. 84), the
formation of the null protein is independent
of the action of DOXol on the cluster and
derives from the attack of anthracycline–iron
complexes on aconitase/IRP1. IRP2 is not
attacked by DOXol; only ROS seem to be active
in this setting, triggering its degradation
(Refs 36, 37).
What are the pathological consequences of the
actionsofDOXolandROSonIRP1andIRP2?The
decline of IRP2 that occurs in response to ROS
formation might serve as a protective stratagem
to facilitate the translation of ferritin mRNA,
and to sequester free iron before it converts O2
 2
and H2O2 into more-potent oxidants. In fact,
DOX treatment increases L-ferritin and
H-ferritin synthesis in H9c2 cardiomyocytes
(Ref. 37) and in mouse hearts (Ref. 85), with a
prominent upregulation of H-ferritin, which has
been proposed to have an antioxidant function
(Refs 17, 86). IRP1 deﬁciency does not alter
DOX-induced iron metabolism changes nor
DOX-induced oxidative damage of the
myocardium, showing that high cardiac IRP1
activity in DOX-treated animals does not
counteract the potential cardio-protective effect
of IRP2 downmodulation (Ref. 85). However,
the conversion of aconitase/IRP1 into a null
protein, by making cells unable to sense iron
levels, may have a major role in inducing
chronic cardiomyopathy, which coincides with
the gradual conversion of DOX to DOXol.
The ability of DOX to modulate the RNA-
binding activity of both IRP1 and IRP2, and
hence the expression of IRE target genes, could
be involved in both the antitumour and
cardiotoxic properties of the drug, and has
produced some important clinical results.
Indeed, it has been shown that combining DOX
with other antineoplastic drugs (e.g. taxanes)
enhances chronic cardiotoxicity because
conversion of DOX to DOXol is accelerated
(Ref. 82). Conversely, anthracyclines with a
lower level of formation of their alcohol
metabolites exhibit reduced cardiotoxicity in
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spreclinical settings, and have entered clinical
trials to assess their efﬁcacy and safety
compared with DOX (Refs 82, 87).
IRPs are also regulated by oxygen tension
(reviewed and discussed in Refs 3, 8), which
differentially regulates the binding activity of
the two IRPs, with a decrease of IRP1,
accompanied by a rise in aconitase activity,
and an increase of IRP2 at low oxygen
concentrations. Why IRP1 and IRP2 respond in
opposite ways to hypoxia remains to be
established, but it should be kept in mind that
at physiological oxygen tension (3–5%) IRP2 is
the predominant RNA-binding protein, thus
possibly explaining its major role in the
regulation of iron metabolism (Fig. 2).
Clinical applications
Hyperferritinaemia with autosomal dominant
congenital cataract – a disorder of iron
metabolism characterised by early-onset,
bilateral nuclear cataracts and elevated serum
ferritin concentrations – is the best-
characterised human disease involving the
IRE–IRP regulatory system (reviewed by
Refs 88, 89). In patients affected by this
disorder, serum iron and transferrin saturation
are normal or low, and body iron (as evaluated
by phlebotomy), is not increased, thus
excluding iron overload as the underlying cause
of hyperferritinaemia. Molecular studies of
tissues from these patients have identiﬁed
multiple point mutations in the IRE of L-ferritin
mRNA, which affects the highly conserved
CAGUGU motif in the IRE loop responsible for
the high-afﬁnity interaction with IRPs
(reviewed by Refs 88, 89). In cultured
lymphoblastoid cells from affected patients, the
mutation was found to abolish the binding of
IRPs and results in constitutively high L-ferritin
synthesis, which correlates with serum ferritin
levels (Ref. 90). The affected subjects show no
haematological or biochemical abnormalities
and the phenotype of this mutation is
characterised only by an accumulation of
L-ferritin in the lens, resulting in cataract,
although a direct relationship between the
mutation and the lens deposit of aggregated
and crystallised ferritin has not been formally
demonstrated.
A point mutation in the IRE of the human
H-ferritin gene (approved gene symbol FTH1)
has been found in members of a Japanese
family affected by iron overload (Ref. 91), but
this ﬁnding has not been conﬁrmed in other
pedigrees.
Further support for the clinical implication of
alterations in the IRE–IRP network is provided
by the expression of ferroportin – the major or
only iron exporter from cells – which can be
altered upon loss of its 50 IRE, as seen in
polycythaemic mice (Ref. 92). Mutations in the
ferroportin mRNA 50 UTR were detected in a
patient with iron overload because of
ferroportin disease (Ref. 93), which may depend
on altered IRE–IRP recognition. Similarly, the
presence of alternative ferroportin transcripts
without an IRE in erythroid cells (Ref. 94)
leaves open the possibility that alterations in
ferroportin mRNA splicing may be relevant in
pathological conditions of altered erythroid
differentiation.
The relevance of dysregulated iron metabolism
in the neurological disorders mentioned above
makes the ﬁnding that polymorphisms in the
promoter region of the IRP2 gene are
statistically associated with Alzheimer disease
potentially interesting (Ref. 95). However, this
preliminary report needs to be conﬁrmed in a
larger independent population, and the
functional signiﬁcance of the haplotype
determined. In addition, the unexpectedly high
IRP1 activity found in patients with Parkinson
disease may account for the low ferritin levels
present in neurons of the substantia nigra in
spite of iron accumulation (Ref. 96).
Research in progress and outstanding
research questions
[4Fe–4S] cluster assembly
In recent years, signiﬁcant advances have been
made to deﬁne the processes and the molecular
participants underlying the assembly of the
IRP1 [4Fe–4S] cluster, indicating that iron
availability is not the only requirement. In fact,
detailed analysis of the pathways of [4Fe–4S]
cluster assembly in mammalian cells has
indicated a key role of mitochondria (Ref. 97),
although a cytosolic [4Fe–4S] cluster assembly
machinery has also been identiﬁed (discussed
in Ref. 8). Impairment of both pathways of
[4Fe–4S] cluster assembly leads to induction of
IRP1-binding activity and may also alter iron
homeostasis. Indeed, it has been found that a
mutation in mitochondrial glutaredoxin, a
protein involved in [4Fe–4S] cluster biogenesis
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favour of the apoform and induces anaemia in
zebraﬁsh by repressing eALAS translation and
hence haem formation. Future work will deﬁne
the role of the ﬂux of iron through the
mitochondrial and cytosolic [4Fe–4S] assembly
pathways in iron homeostasis, possibly leading
to treatments for disease, because mutations in
the human counterparts of the proteins
involved in these processes are likely to be
found in human pathological settings (Ref. 98).
Similarly, the impairment of [4Fe–4S] cluster
formation that characterises Friedreich ataxia
may result in uncontrolled IRP1 activation and
pathological abnormalities of iron homeostasis
(Refs 99, 100).
Structural studies
Insight into the structure–function relationship of
IRPshasbeenrecentlyprovidedbycrystallography
studies.Thecrystalstructureofcytosolicaconitase
has been solved (Ref. 101). Walden et al. (Ref. 26)
also solved the crystal structure of IRP1 bound to
ferritin IRE, detailing the molecular basis
underlying the bifunctionality of this protein.
Further investigation in this ﬁeld, perhaps with a
detailed crystal structure of IRP2 complexed with
IRE, will hopefully determine the speciﬁcity of
the IRE–IRP interaction, the preferential binding
of individual IRPs to a subset of IREs and the
effects of IRP modiﬁcation on its binding activity
and selectivity.
Role of cytosolic aconitase
Under normal conditions, most IRP1/aconitase is
enriched with the [4Fe–4S] cluster and the ratio of
aconitase to IRP1 may exceed 100:1 (Refs 27, 28);
this ﬁnding hence leaves open the question of
the function of cytoplasmic aconitase. A role in
modulating the levels of NADPH and citrate has
been proposed for cytosolic aconitase (Ref. 102).
Mouse models
The role of IRPs in mammalian iron metabolism
has been thoroughly studied in cell culture, but
relatively little in vivo information is available.
Further information regarding their tissue-
speciﬁc regulation could be gained by the
characterisation of knockout mice bearing
conditionally targeted IRP1 and IRP2 loci
generated by tissue-speciﬁc promoters used to
control the cre recombinase (Ref. 46). This
approach could give indications of the
particular role of individual IRPs in speciﬁc
organs or tissues, as suggested by their
different abundances (Ref. 2), and would also
be helpful in understanding their physiological
role. Further information could be obtained by
subjecting animals with tissue-speciﬁc or
general deﬁciency of IRPs to stressful stimuli
thathavebeendemonstratedtoaffectIRPactivity.
New targets
Onemainareaforfutureresearchisexpectedtobe
the search for new IRP targets. Integration of
bioinformatic, biochemical and genomic
approaches has recently led to the identiﬁcation
of new IRP-regulated genes involved in a
number of pathways; implementation of these
strategies will help in the identiﬁcation of other
IRE-regulated genes and lead to a wider
understanding of iron-regulatory networks.
Conclusion
In recent years, the regulation of iron
homeostasis has revealed its increasing
complexity and its multifaceted and unforeseen
interactions with a number of molecular
pathways and processes. The work highlighted
here has shown that signiﬁcant advances have
been made in elucidating the role of the IRE–
IRP network in the post-transcriptional control
of key mRNA molecules involved in iron
metabolism, but also indicates that further
studies are warranted. In particular, we need to
gain further insight into the IRP-mediated
metabolic remodelling that occurs in
response to changes in iron availability and
other iron-independent effectors. This
information might shed light on the role of iron
in the molecular pathophysiology of a wide
range of disorders.
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